AnaptysBio Inc.’s shares rose to a six-month high on Tuesday following the announcement of successful Phase 2b results from ...

RA is an autoimmune disease where the immune system mistakenly attacks the lining of joints, causing inflammation and potential joint damage. Treatment goals for RA include reducing inflammation ...

In February 2025, A naptysBio announced promising results from a global Phase IIb trial (RENOIR) for rosnilimab, a novel ...

A large-scale study reveals that rheumatoid arthritis patients—especially those seropositive or on DMARD therapy—face ...

Symptoms of early arthritis can be easy to overlook, but seeking prompt treatment can help you manage discomfort and protect ...

Women with rheumatoid arthritis have a longer disease duration before being prescribed disease-modifying antirheumatic drugs ...

The spring meeting of the Irish Society for Rheumatology brought together experts from across Ireland and the UK to highlight ...

A commonly used arthritis medication failed to improve symptoms in people with a specific form of knee osteoarthritis, according to an article published June 2 in JAMA Internal Medicine. In a ...

Rheumatoid arthritis is less common than osteoarthritis, affecting around 514,000 Australians. It mostly impacts the wrists and small joints in the hands and feet, though larger joints such as the ...

Half of rheumatoid arthritis patients in remission flared after stopping medication in the BIO-FLARE study, but new findings help predict who is at highest risk.